PMA device
Floseal Hemostatic Matrix
Baxter Healthcare Corp · Agent, Absorbable Hemostatic, Collagen Based (LMF, Class III) · First FDA decision Mar 10, 2005, newest Aug 21, 2015Surgical bleeding and hemostasis
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
7
PMA pathway
Device trials
13
Naming "Floseal"
MAUDE reports
267
Brand "Floseal", since 2015
PubMed studies
291
Mentioning "Floseal"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Floseal Hemostatic Matrix
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 7 decisions filed under this name.
- FLOSEAL HEMOSTATIC MATRIXPMA supplement
P990009-S040 · Decided Aug 21, 2015 · 155 days after receipt · Normal 180 Day Track No User Fee
Device type: Agent, absorbable hemostatic, collagen based (LMF) · General & Plastic Surgery
- FLOSEAL HEMOSTATIC MATRIXPMA supplement
P990009-S039 · Decided Feb 26, 2015 · 216 days after receipt · Normal 180 Day Track No User Fee
Device type: Agent, absorbable hemostatic, collagen based (LMF) · General & Plastic Surgery
- FLOSEAL HEMOSTATIC MATRIXPMA supplement
P990009-S037 · Decided May 27, 2014 · 355 days after receipt · Normal 180 Day Track
Device type: Agent, absorbable hemostatic, collagen based (LMF) · General & Plastic Surgery
3 more FDA decisions with a free account
Older decisions: P990009-S013
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Floseal", any status and sponsor, newest update first.
- Study of Collagen-Based Thrombin Hemostat for the Control of Bleeding in Spinal SurgeryPivotal-lookingCompleted
DALIM TISSEN Co., Ltd.Not on our public-company list
NCT07354178 · 130 participants · Start Oct 22, 2024 · Primary completion Jun 19, 2025
Device: CollaStat®; Floseal® · For: Spinal Tumor; Spinal Injury; Hemostasis and 3 more
Sites: Seoul, South Korea; Yongin-si, South Korea · 3 sites in all
- Tract Closure in PCNLPivotal-lookingRecruiting
Icahn School of Medicine at Mount SinaiAcademic, hospital or other
NCT07668817 · 114 participants (planned) · Start Nov 2026 · Primary completion May 2028
Device: Floseal; Surgicel · For: Nephrolithiasis
Sites: New York, New York
Johns Hopkins UniversityAcademic, hospital or other
NCT04058665 · 300 participants · Start Jun 18, 2019 · Primary completion Mar 1, 2022
Device: Floseal · For: Blood Loss
Sites: Baltimore, Maryland
10 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Floseal", and for the whole product code for context.
This brand
267 reports: 106 malfunction, 150 injury, 9 death
Whole product code LMF
1,445 reports: 207 malfunction, 1,171 injury, 61 death
Newest reports for this brand
- FLOSEAL HEMOSTATIC MATRIXMalfunction
1416980-2026-02984 · Received Sep 17, 2026
Device type: Absorbable Collagen Hemostatic Agent With Thrombin (PMX)
Device problem as coded: Device Damaged Prior to Receipt by User
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- FLOSEALDeath
1416980-2026-02906 · Received Sep 8, 2026 · Event dated Apr 14, 2026
Device type: Agent, Absorbable Hemostatic, Collagen Based (LMF)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Bradycardia; Respiratory Insufficiency; Appropriate Clinical Signs, Symptoms and Conditions Term/Code Not Available
- FLOSEAL HEMOSTATIC MATRIXMalfunction
1416980-2026-02510 · Received Jul 31, 2026
Device type: Absorbable Collagen Hemostatic Agent With Thrombin (PMX)
Device problem as coded: Manufacturing, Packaging or Shipping Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0667-2024 · Started Dec 6, 2023 · Posted by FDA Jan 5, 2024
Reason given: Cardiovascular Surgery marketing brochure (US-AS46-220001) that was distributed for the products listed below contains inaccurate content that does not align with some of the products Instructions for Use (IFU) or Prescribing Information (PI).
Cause as FDA categorized it: Under Investigation by firm · Device type: Absorbable Collagen Hemostatic Agent With Thrombin (PMX)
Z-2957-2018 · Started May 30, 2018
Reason given: Baxter r recalled this device due to the use of an incorrect plastic formulation in the manufacture of the blue luer component of the FLOSEAL malleable tips.
Cause as FDA categorized it: Mixed-up of materials/components · Device type: Absorbable Collagen Hemostatic Agent With Thrombin (PMX)
Z-2340-2008 · Started Jul 31, 2008 · Posted by FDA Sep 20, 2008
Reason given: The recall is being conducted as a precautionary measure due to potential discoloration of the FloSeal material noted in six (6) non-medical complaints during delivery by the Endoscopic Applicator.
Cause as FDA categorized it: Pending · Device type: Agent, Absorbable Hemostatic, Collagen Based (LMF)
Published research
The most relevant PubMed records for "Floseal"[tiab]. The summary above synthesizes these.
- Floseal-induced small bowel obstruction.
Ashraf H, Low N, Spiro C, et al. · J Surg Case Rep · 2022Case Reports
- FLOSEAL Versus SURGIFLO in Lumbar Surgery: Similar Outcomes, Different Costs in a Matched Cohort Analysis.
Ye IB, Thomson AE, Smith RA, et al. · World Neurosurg · 2023
- Epistaxis Treatment Options: Literature Review.
Mylonas S, Skoulakis C, Nikolaidis V, et al. · Indian J Otolaryngol Head Neck Surg · 2023
- The utility of FloSeal haemostatic agent in the management of epistaxis.
Khan MK, Reda El Badawey M, Powell J, et al. · J Laryngol Otol · 2015Evaluation Study
- Use of Floseal®, a human gelatine-thrombin matrix sealant, in surgery: a systematic review.
Echave M, Oyagüez I, Casado MA · BMC Surg · 2014Research Support, Non-U.S. Gov't, Systematic Review
- Gelatin-Based Hemostatic Agents: Histopathologic Differences.
Wolkow N, Jakobiec FA, Yoon MK · Ophthalmic Plast Reconstr Surg · 2018Research Support, Non-U.S. Gov't
- FloSeal reduces the incidence of lymphoceles after lymphadenectomies in laparoscopic and robot-assisted extraperitoneal radical prostatectomy.
Waldert M, Remzi M, Klatte T, et al. · J Endourol · 2011
- The effectiveness of FloSeal matrix hemostatic agent in thyroid surgery: a prospective, randomized, control study.
Testini M, Marzaioli R, Lissidini G, et al. · Langenbecks Arch Surg · 2009Comparative Study, Randomized Controlled Trial
- Comparison of Floseal® and Tranexamic Acid for Bleeding Control after Total Knee Arthroplasty: a Prospective Randomized Study.
Helito CP, Bonadio MB, Sobrado MF, et al. · Clinics (Sao Paulo) · 2019Comparative Study, Randomized Controlled Trial
- Evaluation of FloSeal as a potential intracavitary hemostatic agent.
Klemcke HG · J Trauma · 2006
- Use of FloSeal hemostatic sealant in transsphenoidal pituitary surgery: technical note.
Ellegala DB, Maartens NF, Laws ER · Neurosurgery · 2002Review
- Use of FLOSEAL® as a scaffold and its impact on induced neural stem cell phenotype, persistence, and efficacy.
Bomba HN, Carey-Ewend A, Sheets KT, et al. · Bioeng Transl Med · 2022
Other devices of this type
Also filed under product code LMF.
- SURGIFOAM® Absorbable Gelatin SpongeFerrosan Meidcal Devices A/S · PMA 2026
- Vitagel Surgical HemostatStryker Corp. · PMA 2013
- SURGIFLO Hemostatic Matrix Kit with ThrombinFerrosan Meidcal Devices A/S · PMA 2025
- Helistat Absorbable Collagen Hemostatic Sponge/OraFOAM Absorbable Collagen Hemostatic SpongeIntegra LifeSciences Corporation · PMA 2019
- Instat Collagen Absorbable HemostatETHICON, Inc. · PMA 2007
- Avitene Flowable Collagen HemostatDavol Inc., Sub. C. R. Bard, Inc. · PMA 2025
- Collastat Absorbable Collagen Hemostatic AgentsIntegra LifeSciences Corporation · PMA 2009
- Floseal (R) Matrix Hemostatic Sealant and Proceed (Tm) Hemostatic SealantBaxter Healthcare Corp · PMA 2001
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.